

# Jean Lee, PharmD, MS

jeanlee2424@gmail.com | 267-490-7903 | [LinkedIn](#)

---

PharmD-trained [HEOR/RWE] researcher with expertise in real-world data, statistical analysis (i.e. SAS, SQL, R), and cost-effectiveness modeling. Experience in protocol development, vendor coordination, supporting AMCP dossier development and evidence generation strategies across oncology and cardiovascular portfolios.

## Professional Work Experiences

---

### Post-Doctoral Fellow, Health Economics and Outcomes Research (HEOR)

*Bayer Pharmaceuticals*

July 2024 – Present

*Whippany, NJ*

- Led design and execution of real-world evidence (RWE) study using large administrative claims databases (e.g., Optum) to generate payer-relevant evidence supporting post-launch access and formulary positioning for oncology assets
- Owned end-to-end RWE project management — from protocol development through data analysis, interpretation, and dissemination via final reports, study summary decks, and scientific congress outputs — delivering timely, high-quality evidence packages that translated complex findings into decision-ready insights for other stakeholders
- Developed publication plans for RWE studies, strategically sequencing congress presentations and peer-reviewed manuscripts to maximize evidence visibility at key launch milestones — ensuring findings reached payers and clinicians through the right channels at the right time
- Drove development of cost-effectiveness analyses and budget impact models (BIMs) for late-stage pipeline (Phase 3) and approved products (e.g., asundexian and sevabertinib), aligning economic evidence with U.S. payer requirements and strengthening the value narrative at critical pre- and post-launch decision points
- Shaped AMCP dossier development by synthesizing clinical, economic, and RWE into a cohesive, payer-ready submission — directly supporting formulary decision-making and access for patients who depend on timely coverage
- Evaluated patient-reported outcome measures for feasibility, licensing, and implementation fit, enabling the oncology evidence team to proactively plan clinically meaningful endpoints for post-launch studies
- Conducted systematic literature reviews (SLRs) on real-world treatment patterns in HER2+ NSCLC identifying evidence gaps that grounded the product value narrative in the actual standard of care landscape
- Developed a comprehensive HEOR strategy overview for an advisory board, integrating clinical and economic evidence with stakeholder value messages and identifying payer-relevant evidence gaps — translating expert input into a prioritized RWE roadmap that guided future research investment decisions

### Evidence Generation & Value Communications Intern

*Cencora*

Sep 2023 – Nov 2023

*Conshohocken, PA*

- Developed a new business development primer synthesizing pipeline landscapes, competitive dynamics, and unmet need assessments using Biomedtracker — giving client companies a strategic reference to evaluate partnership opportunities and prioritize assets based on market potential and evidence gaps
- Conducted Health Technology Assessment (HTA) reviews across multiple therapeutic areas to map payer evidence expectations and reimbursement drivers, directly informing how value communication strategies were framed for client engagements
- Executed targeted literature reviews and market landscape analyses, translating complex scientific findings into actionable deliverables that enabled faster, evidence-grounded decisions on evidence strategy direction

### Global Pricing & Market Access Intern

*Bristol Myers Squibb*

Aug 2023 – Sep 2023

*Princeton, NJ*

- Evaluated global evidence requirements for pricing and reimbursement by reviewing HTA submissions (e.g., France) and published RWE studies, identifying strategic gaps that informed optimal evidence planning across key markets
- Created how major HTA bodies assess indirect treatment comparisons (ITCs), producing reimbursement positioning implications that supported the Global Market Access team's submission planning
- Developed and presented insights on RWE's role in demonstrating clinical and economic value — directly influencing the HEOR team's evidence generation priorities going forward

### 340B Analyst Extern — Lead Extern

*University of Illinois Hospital & Health Sciences System (UI Health)*

Mar 2021 – May 2023

*Chicago, IL*

- Led monthly 340B compliance reviews by reconciling qualified claims across clinic locations, insurance types, and prescribing providers — ensuring accurate program utilization and reducing federal audit risk
- Optimized the split-billing software by identifying eligible dispenses and resolving discrepancies, improving accumulation accuracy and operational efficiency across the program
- Developed and presented performance reports on cost savings and operational improvements to leadership at quarterly and annual committee meetings, directly informing strategic decision-making

## Academic Research Experiences

---

### Post-Doctoral Fellow, HEOR

University of Washington, CHOICE Institute

July 2024 – June 2025

Seattle, WA

- Designed and conducted retrospective RWE claims studies using MarketScan datasets
  - Utilized SAS/SQL to build the patient cohort and clean datasets
  - Performed statistical analyses in R, such as negative binomial regression
  - Executed the full research lifecycle, from research question to manuscript development
- Developed a cost-effectiveness analysis comparing two therapies with standard of care
- Built a Markov model in Microsoft Excel to conduct one-way sensitivity analysis (OWSA), probabilistic sensitivity analysis (PSA), and value-of-information (VOI) assessments

### Pharmacy Student Researcher

Research Title: *Cost-Effectiveness Analysis of Emergency Department-Based HCV Screening and Linkage-To-Care Program*

Mar 2021 – Dec 2022

Chicago, IL

- Conducted systematic literature reviews (SLR) to inform model inputs and contributed to a peer-reviewed publication as a co-author, demonstrating strong evidence synthesis and scientific writing skills

## Publications and Presentations

---

### Manuscripts

- **Lee J.**, Hansen R., Yeung C., Comparing Health Resource Utilization and Costs in HFpEF patients using SGLT2-inhibitor Combination Treatments (*Manuscript in submission*)
- Choi S., Umashankar K., Maheswaran A., Martin M., **Lee J.**, Odishoo M., Lin J., Touchette D., Cost-Effectiveness Analysis of Emergency Department-Based HCV Screening and Linkage-To-Care Program. *BMC Health Services Research*. 2024;24(1):1308. doi: 10.1186/s12913-024-11793-4

### Scientific Presentations

- **Lee J.**, Hansen R., Cost-Effectiveness Analysis of Baricitinib and Ritlecitinib for Alopecia Areata in the U.S. Presented at: ISPOR; May 14-16, 2025; QC, Canada
- **Lee J.**, Hansen R., Treatment patterns and Efficacy/Safety of the drugs in HER2+ NSCLC: A Systematic Literature Review. Presented at: ISPOR; May 14-16, 2025; QC, Canada
- Kim K., **Lee J.**, Hart M., Garofalo J., Mucksavage J., Time to Stable Therapeutic Anticoagulation Using Weight-Based IV Heparin Dosing Clinical Decisions Support Program. Presented at: THSNA; April 4-6, 2024; Chicago, IL
- Poondi N., **Lee J.**, Wu A., Snell B., Cortez C., Assessing the Impact of Pharmacy Student Contributions to 340B Drug Discount Participation. Presented at: ASHP Midyear; December 5-9, 2021; virtual meeting
- Head M., Haley V., Durden E., Caproni S., Ko G., Willey V., Hopkins K., **Lee J.**, Chaturvedi S., Lisabeth L., Incidence and Costs of Recurrent Stroke Events in Patients with IS or TIA of Non-Cardioembolic Origin. Acceptance Pending at: ISPOR; May 17-20, 2026; Philadelphia, PA
- Song J., Durden E., Sundar M., Fried L., **Lee J.**, Betts K., Incidence and Costs of Secondary Stroke Events in Patients with Ischemic Stroke or Transient Ischemic Attack of Non-Cardioembolic Origin. Acceptance Pending at: ISPOR; May 17-20, 2026; Philadelphia, PA
- Song J., Durden E., Sundar M., Fried L., **Lee J.**, Betts K., Healthcare Resource Utilization and Costs of Recurrent Strokes in Medicare Fee-For-Service Beneficiaries in the United States. Acceptance Pending at: ISPOR; May 17-20, 2026; Philadelphia, PA
- Dayer V., Campbell D., Ramsey S., Kalayeh B., Grossman J., **Lee J.**, Appukkuttan S., Budget Impact Model of Sevabertinib for Previously Treated HER2-mutant Advanced Non-Squamous NSCLC. Acceptance Pending at: ISPOR; May 17-20, 2026; Philadelphia, PA
- Huhmann L., La J., Dulberger K., Schoen M., Fillmore N., Paller C., **Lee J.**, Kalayeh B., Goel H., Appukkuttan S., Major Adverse Cardiovascular Events in Androgen Receptor Signaling Inhibitor-Treated Patients with Metastatic Castration Sensitive Prostate Cancer (MACE-ARMS). Acceptance Pending at: ASCO Annual; May 29-June 2, 2026; Chicago, IL

## Education

---

### Master of Science, Health Economics and Outcomes Research

University of Washington, CHOICE Institute

June 2025

Seattle, WA

- Master's Thesis: *Comparing Healthcare Resource Utilization and Costs in HFpEF patients using SGLT2-inhibitor Combination Treatments*

### Doctor of Pharmacy (PharmD)

University of Illinois at Chicago, College of Pharmacy

May 2024

Chicago, IL

- Pharmacoepidemiology Certificate: May 2023